EGFR and triple-negative breast carcinoma: Furthermore, they showed that metformin targets the cholesterol biosynthesis pathway and stabilizes GM1 lipid rafts, reducing membrane EGFR (epidermal growth factor receptor) signaling and its activation in triple-negative breast cancer.